AbbVie Inc (ABBV)vsArdent Health Partners, Inc. (ARDT)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ARDT
Ardent Health Partners, Inc.
$9.76
+1.35%
HEALTHCARE · Cap: $1.38B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 867% more annual revenue ($61.16B vs $6.32B). ABBV leads profitability with a 6.9% profit margin vs 2.1%. ARDT trades at a lower P/E of 10.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ARDT
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for ARDT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
2.1% margin — thin
Elevated debt levels
Revenue declined 0.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.84 is elevated, increasing financial risk. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a premier healthcare organization focused on delivering high-quality, patient-centered care through a comprehensive network of hospitals and outpatient facilities. Renowned for its extensive portfolio of acute care hospitals, Ardent is dedicated to innovating healthcare solutions that meet the diverse and evolving needs of communities. With a solid financial structure and a strategic vision for growth, the company is well-positioned to enhance access to healthcare and improve patient outcomes in a complex and dynamic industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?